NPI registry status
Active
2026 NPPES data Dermatopathology Physician NPI 1417949777 M.D.
Verify on CMS → Matthew Reschly, M.D.
Dermatopathology Physician in Lawrenceville, Georgia.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 577 in Dermatopathology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
870
Medicare Part D claims · 279 beneficiaries · Dermatopathology Physician avg: 695
Generic prescribing
96%
generic claims · 4% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$2.1K
140 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Matthew Reschly, M.D. filed 870 Medicare Part D claims in 2024 as a Dermatopathology Physician in Lawrenceville, Georgia, prescribing 96% generic.
- 870
- Part D claims, 2024
- 96%
- generic prescribing
- $2.1K
- industry payments (Sunshine Act)
- ≥72nd
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Matthew Reschly, M.D.
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1417949777), first enumerated 08/22/2005.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 870 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Practices in an ABMS-board-eligible specialty; board certification not confirmed in federal records.
- Reported
Industry payment transparency
$2.1K in reported industry payments (140 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1417949777 · Dermatopathology Physician
NPI-10 · ENUM-LEGACY · TAX-NARROW · RX-LIGHT · BOOK-THIN · PHOTO-ENUM
- NPI-10 1417949777
- ENUM-LEGACY 2005
- TAX-NARROW 577
- RX-LIGHT 870
- BOOK-THIN 15 in Georgia
- PHOTO-ENUM Edward Chan · 2005
Matthew Reschly, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
870 ≥ 72nd percentile 72% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
◑
Board-eligible specialty (heuristic, not verified)
Matthew Reschly, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Matthew Reschly, M.D.?
Quality data not reportedPrimary specialty
Dermatopathology Physician
Medicare Part D claims
870 25% vs specialty avg
Specialty distribution in Georgia
How Dermatopathology Physician compares to other specialties among Georgia providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Dermatopathology Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1417949777 |
|---|---|
| Specialty | Dermatopathology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 08/22/2005 |
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Matthew Reschly, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$2.1K
Largest payer
ABBVIE INC.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Generic-heavy
Matthew Reschly, M.D. - brand share 4.0%
Dermatopathology Physician average
4% brand-name claims vs 96% generic, on 870 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
870
Total Claims
$135K
Total Drug Cost
279
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,100.2
- Total Day Supply
- 29,712
- Brand vs Generic
- 4% brand / 96% generic
- Brand Drug Cost
- $117K
- Generic Drug Cost
- $18K
- Antibiotic Claims
- 94
Patient Demographics
- Average Patient Age
- 73.3 years
- Avg HCC Risk Score
- 1.01
- Gender Split
- 50% female / 50% male
- Age Distribution
- <65: 16, 65-74: 136, 75-84: 103, 85+: 24
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Matthew Reschly, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2024
- Minoxidil
Minoxidil
104 claims
- Fluocinonide
Fluocinonide
85 claims
- Fluconazole
Fluconazole
76 claims
- Ketoconazole
Ketoconazole
76 claims
- Triamcinolone Acet…
Triamcinolone Acetonide
61 claims
- Escitalopram Oxalate
Escitalopram Oxalate
51 claims
- Clobetasol Propion… 41
Clobetasol Propionate
41 claims
- Doxycycline Hyclate 37
Doxycycline Hyclate
37 claims
| Drug | Claims |
|---|---|
| Minoxidil | 104 |
| Fluocinonide | 85 |
| Fluconazole | 76 |
| Ketoconazole | 76 |
| Triamcinolone Acetonide | 61 |
| Escitalopram Oxalate | 51 |
| Clobetasol Propionate | 41 |
| Doxycycline Hyclate | 37 |
| Fluorouracil | 29 |
| Minocycline Hcl | 21 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Dermatopathology Physician Overview
How Matthew Reschly, M.D. fits within the Dermatopathology Physician landscape nationally.
577
Dermatopathology Physician Providers in US
48
States with Dermatopathology Physician
695
Avg Claims per Provider
Matthew Reschly, M.D.'s 870 claims are above the specialty average of 695.
Nationwide Dermatopathology Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Reschly, both outside Georgia so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2005)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Dermatopathology Physician Providers in Georgia
Other clinicians with the same primary specialty enrolled in Georgia, drawn from the same CMS NPPES roster as Reschly.
One of 15 Dermatopathology Physician providers enrolled in Georgia, 5 are shown here.
Dr. Jill Buckthal-McCuin
MD
Greensboro, GA
Dr. Allen Filstein
M.D.
Conyers, GA
Dr. Marian Finan
M.D.
Atlanta, GA
Dr. Sion Jasmine
MD
Snellville, GA
Dr. Carolina Montes
MD
Alpharetta, GA
Compare Dermatopathology Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Matthew Reschly, M.D.'s specialty? ▼
Matthew Reschly, M.D. specializes in Dermatopathology Physician and practices in Lawrenceville, Georgia. Credentials: M.D..
How much does Matthew Reschly, M.D. prescribe under Medicare Part D? ▼
In 2024, Matthew Reschly, M.D. wrote 870 Medicare Part D claims totaling $135K in drug costs for 279 beneficiaries.
Where is Matthew Reschly, M.D. located? ▼
Matthew Reschly, M.D. is located at 2000 RIVERSIDE PKWY STE 100, Lawrenceville, GA, 30043. Phone: (470) 273-7233.
What is Matthew Reschly, M.D.'s NPI number? ▼
Matthew Reschly, M.D.'s National Provider Identifier (NPI) is 1417949777, issued on 08/22/2005.
Does Matthew Reschly, M.D. prescribe more brand-name or generic drugs? ▼
Matthew Reschly, M.D.'s prescribing is 4% brand-name and 96% generic drugs by claim count, with $117K in brand drug costs.
How many Dermatopathology Physician providers are there in the US? ▼
There are 577 Dermatopathology Physician providers across 48 states in the US. The average Dermatopathology Physician provider writes 695 Medicare Part D claims per year.
What drugs does Matthew Reschly, M.D. prescribe most often? ▼
Based on 2024 Medicare Part D data, Matthew Reschly, M.D.'s most frequently prescribed drugs include Minoxidil, Fluocinonide, Fluconazole. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Matthew Reschly, M.D. accept Medicare? ▼
Matthew Reschly, M.D. appears in CMS Medicare data with 870 Part D claims and 279 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Matthew Reschly, M.D.'s credentials? ▼
Matthew Reschly, M.D.'s NPI is 1417949777 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.